CTXR

NASDAQ 已收盘

Citius Pharmaceuticals

0.51 USD
▲+0.01+2.27%
盘后 0.51 -0.65%
2026-11-20
市值
$13.96M
市盈率
—
EPS
-2.12
股息率
—
52 周区间
0.37 – 1.54
成交量
183.70K
Beta
1.04
目标价
—
52W 低 0.3752W 高 1.54
价格走势

公司简介

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company’s late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and Nove...